Brazil’s health regulator Anvisa approved on Friday a request from the biomedical institute Fiocruz to import more doses of the vaccine developed by AstraZeneca and the Oxford University of the Serum Institute of India, without specifying how many.
Also on Friday, Fiocruz said in a statement, without referring to Anvisa’s approval, that it was negotiating imports of 2 million more doses from the Serum Institute, in addition to the 2 million already agreed.
Brazil, which is in the middle of the second deadliest COVID-19 outbreak in the world after the United States, has so far only authorized the AstraZeneca vaccine and one developed by China SinoVac for emergency use.
.
She is a freelance blogger, writer, and speaker, and writes for various entertainment magazines.